C4 Therapeutics, Inc.
US ˙ NasdaqGS ˙ US12529R1077

Introduction

This page provides a comprehensive analysis of the known insider trading history of Marc A Cohen. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Marc A Cohen has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CCCC / C4 Therapeutics, Inc. Director 1,118
US:FREQ / Frequency Therapeutics Inc Director 14,846
Chairman, CEO, Treas & Secy, Director, 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Marc A Cohen. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CCCC / C4 Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CCCC / C4 Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-10-06 CCCC COHEN MARC A 5,030 19.0000 5,030 19.0000 95,570 352 50.5 158,445 165.79

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CCCC / C4 Therapeutics, Inc. Insider Trades
Insider Sales CCCC / C4 Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CCCC / C4 Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CCCC / C4 Therapeutics, Inc. Insider Trades
Insider Purchases KRRO / Korro Bio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CCCC / C4 Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-10-07 FREQ COHEN MARC A 17,857 14.0000 17,857 14.0000 249,998 121 27.55 241,962 96.79

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KRRO / Korro Bio, Inc. Insider Trades
Insider Sales KRRO / Korro Bio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CCCC / C4 Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KRRO / Korro Bio, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Marc A Cohen as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-01-18 2022-01-04 4 CCCC C4 Therapeutics, Inc.
Common Stock
A - Award 657 1,118 142.52 31.58 20,748 35,306
2021-10-05 2021-10-04 4 CCCC C4 Therapeutics, Inc.
Common Stock
A - Award 461 461 44.99 20,740 20,740
2021-07-07 2021-07-02 4 CCCC C4 Therapeutics, Inc.
Common Stock
A - Award 522 6,641 8.53 39.72 20,734 263,781
2021-06-21 2021-06-17 4 FREQ Frequency Therapeutics, Inc.
Stock Option
A - Award 14,846 14,846
2021-06-17 2021-06-15 4 CCCC C4 Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 23,500 23,500
2021-06-14 2021-06-14 4 CCCC C4 Therapeutics, Inc.
Common Stock
J - Other 22,598 1,874,805 1.22
2021-06-14 2021-06-14 4 CCCC C4 Therapeutics, Inc.
Common Stock
J - Other 92,817 98,936 1,516.87
2021-04-06 2021-04-05 4 CCCC C4 Therapeutics, Inc.
Common Stock
A - Award 553 6,119 9.94 37.51 20,743 229,524
2021-02-19 2021-02-18 4 CCCC C4 Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -536 3,209 -14.31
2021-02-19 2021-02-18 4 CCCC C4 Therapeutics, Inc.
Common Stock
M - Exercise 536 5,566 10.66 2.11 1,131 11,744
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -20,952,403 0 -100.00
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -12,500,000 0 -100.00
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Series Seed Preferred Stock
C - Conversion -2,000,000 0 -100.00
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Common Stock
P - Purchase 5,030 5,030 19.00 95,570 95,570
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Common Stock
C - Conversion 2,484,425 2,484,425
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Common Stock
C - Conversion 1,482,183 1,852,207 400.56
2020-10-06 2020-10-06 4 CCCC C4 Therapeutics, Inc.
Common Stock
C - Conversion 237,149 370,024 178.48
2020-10-05 2020-10-01 4 CCCC C4 Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 17,786 17,786
2020-10-05 2020-10-01 4 CCCC C4 Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 725,002 725,002
2020-10-01 3 CCCC C4 Therapeutics, Inc.
Common Stock
132,875
2020-06-12 2020-06-11 4 FREQ Frequency Therapeutics, Inc.
Stock Option
A - Award 14,846 14,846
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Stock Option
M - Exercise -20,778 0 -100.00
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Stock Option
M - Exercise -20,778 0 -100.00
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Stock Option
M - Exercise -21,827 32,918 -39.87
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Stock Option
M - Exercise -16,691 50,072 -25.00
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Stock Option
M - Exercise -8,042 12,063 -40.00
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Common Stock
M - Exercise 20,778 605,820 3.55 3.37 70,022 2,041,613
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Common Stock
M - Exercise 20,778 605,820 3.55 3.37 70,022 2,041,613
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Common Stock
M - Exercise 21,827 564,264 4.02 3.37 73,557 1,901,570
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Common Stock
M - Exercise 16,691 542,437 3.17 0.61 10,182 330,887
2020-02-03 2020-01-30 4 FREQ Frequency Therapeutics, Inc.
Common Stock
M - Exercise 8,042 525,746 1.55 0.61 4,906 320,705
2019-12-05 2019-12-03 4 FREQ Frequency Therapeutics, Inc.
Stock Option
A - Award 20,778 20,778
2019-10-08 2019-10-07 4 FREQ Frequency Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -163,388 0 -100.00
2019-10-08 2019-10-07 4 FREQ Frequency Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -543,219 0 -100.00
2019-10-08 2019-10-07 4 FREQ Frequency Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -2,292,235 0 -100.00
2019-10-08 2019-10-07 4 FREQ Frequency Therapeutics, Inc.
Common Stock
P - Purchase 17,857 17,857 14.00 249,998 249,998
2019-10-08 2019-10-07 4 FREQ Frequency Therapeutics, Inc.
Common Stock
C - Conversion 445,229 517,704 614.32
2019-10-02 3 FREQ Frequency Therapeutics, Inc.
Common Stock
144,950
2019-10-02 3 FREQ Frequency Therapeutics, Inc.
Common Stock
144,950
2019-10-02 3 FREQ Frequency Therapeutics, Inc.
Common Stock
144,950
2012-12-20 2012-12-18 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
D - Sale to Issuer -5,290 0 -100.00 41.78 -221,016
2012-12-20 2012-12-18 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
F - Taxes -3,861 5,290 -42.19 41.72 -161,081 220,699
2012-12-20 2012-12-18 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
U - Other -2,782,748 9,151 -99.67 41.78 -116,263,211 382,329
2012-11-15 2012-11-14 4 OPNT OPNET TECHNOLOGIES INC
Stock Option (Right to Buy)
M - Exercise -48,000 0 -100.00
2012-11-15 2012-11-14 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
M - Exercise 48,000 2,791,899 1.75 11.75 564,000 32,804,813
2012-06-15 2012-06-14 4 OPNT OPNET TECHNOLOGIES INC
Stock Option (Right to Buy)
M - Exercise -38,000 0 -100.00
2012-06-15 2012-06-14 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
S - Sale -12,323 2,743,899 -0.45 24.68 -304,132 67,719,427
2012-06-15 2012-06-14 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
M - Exercise 38,000 2,756,222 1.40 5.85 222,300 16,123,899
2012-06-15 2012-06-13 4 OPNT OPNET TECHNOLOGIES INC
Stock Option (Right to Buy)
M - Exercise -12,000 38,000 -24.00
2012-06-15 2012-06-13 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
S - Sale -12,000 2,718,222 -0.44 24.32 -291,840 66,107,159
2012-06-15 2012-06-13 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
M - Exercise 12,000 2,730,222 0.44 5.85 70,200 15,971,799
2012-02-13 2012-02-09 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
A - Award 1,167 2,718,222 0.04
2012-02-10 2011-05-11 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
A - Award 878 2,671,462 0.03
2012-02-10 2011-02-06 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
F - Taxes -215 2,669,415 -0.01 30.11 -6,474 80,376,086
2012-02-07 2012-02-06 4 OPNT OPNET TECHNOLOGIES INC
Common Stock
F - Taxes -215 2,716,392 -0.01 38.22 -8,217 103,820,502
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)